CompletedNCT05184504
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Latin American Cooperative Oncology Group
- Principal Investigator
- André Poisl FayLatin American Cooperative Oncology Group
- Intervention
- Observational study(other)
- Enrollment
- 211 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (16)
- CINPAM - Centro Integrado de Pesquisa da Amazônia, Manaus, Amazonas, Brazil
- Oncocentro Ceará (Rede D'or), Fortaleza, Ceará, Brazil
- Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO), Cachoeiro de Itapemirim, Espírito Santo, Brazil
- Santa Casa de Misericórdia de Feira de Santana, Feira de Santana, Estado de Bahia, Brazil
- NOB - Núcleo de Oncologia da Bahia (Oncoclínicas), Salvador, Estado de Bahia, Brazil
- Onco-Vida Instituto Especializado de Oncologia, Brasília, Federal District, Brazil
- Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho, São Luís, Maranhão, Brazil
- Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo, Campo Grande, Mato Grosso do Sul, Brazil
- ICTR - Instituto do Câncer e Transplante de Curitiba, Curitiba, Paraná, Brazil
- Hospital Napoleão Laureano, João Pessoa, Paraíba, Brazil
- Hospital Porto Dias, Belém, Pará, Brazil
- CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande do Sul, Brazil
- Clínica de Hematologia e Oncologia Viver, Santa Maria, Rio Grande do Sul, Brazil
- CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas), Rio de Janeiro, Brazil
- Hemomed Instituto de Oncologia e Hematologia, São Paulo, Brazil
- +1 more locations on ClinicalTrials.gov
Collaborators
Ipsen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05184504 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma